The U.S. Food and Drug Administration has approved Exablate Neuro, Insightec’s platform for noninvasive, MRI-guided focused ultrasound therapy, for the bilateral treatment of motor symptoms in patients with advanced Parkinson’s disease who no longer respond to medication. The therapy targets regions within the pallidothalamic tract, a brain pathway…
Target enrollment for a Phase 1b clinical study assessing the safety and tolerability of GT-02287 in people with Parkinson’s disease is complete, three months ahead of the original goal, the therapy’s developer said. After enrolling the first 16 participants, the Phase 1b clinical trial (NCT06732180) is recruiting up…
People in the prodromal, or presymptomatic, stage of Parkinson’s disease show increased immune activity, with T cells targeting the proteins PINK1 and alpha-synuclein at levels similar to those seen in patients already diagnosed with the neurodegenerative condition, a new study reports. These two proteins — PINK1 and alpha-synuclein —…
A three-year grant from Parkinson Canada will allow a Canadian researcher to investigate the mechanisms by which a recently found mutation in the RAB32 gene is linked to Parkinson’s disease. The $135,000 grant will allow Jay Penney, PhD, associate professor at the University of Prince Edward Island in…
VTX3232, an NLRP3 inhibitor being developed by Ventyx Biosciences as a treatment for Parkinson’s disease, was found to be safe and well tolerated after nearly one month of daily dosing in a clinical trial involving people with early-stage disease, according to the company. With these results, VTX3232 met…
Roche said it will launch a Phase 3 trial testing prasinezumab, an anti-alpha-synuclein antibody, as a potential treatment for early-stage Parkinson’s disease. The decision follows data from two Phase 2 trials showing prasinezumab had potential clinical efficacy at slowing motor symptom progression and reducing motor complications as an add-on…
Rune Labs and the Parkinson’s Foundation are partnering on a clinical program to identify genetic and digital biomarkers showing how genetics and daily symptoms are connected in people with Parkinson’s disease, with the aim of speeding diagnosis, improving clinical trial design, and supporting the development of more targeted treatments. The…
Cure Parkinson’s is funding SLEIPNIR, a multiarm clinical trial platform that will simultaneously test up to three disease-modifying treatments for Parkinson’s disease — assessing whether any of them can engage with their intended targets in the brain. The results are expected to help decide if these treatments should…
Microglia-driven inflammation plays an early, key role in the development of neurodegenerative diseases, including Parkinson’s disease, by contributing to the spread of abnormal protein clumps in the brain. That’s according to study results published by a team of South Korean researchers and highlighted by Zyversa Therapeutics, which recently…
Multiple doses of apathy treatment IRL757 for Parkinson’s disease and other neurological disorders were well tolerated and presented a favorable pharmacological profile in the second part of a Phase 1 trial. This part of the Phase 1 clinical trial (NCT06493045) tested the safety and tolerability of multiple ascending…
Get regular updates to your inbox.
